Emyria has received a R&D Tax incentive cash refund of $2,094,701, part of an Australian Government program to support Australian companies to undertake R&D activities in Australia.

“This substantial refund reflects the scale of Emyria’s research and development investment during the last financial year,” said Managing Director Dr Michael Winlo.

“Combined with our recent strategic placement, this R&D tax incentive cash refund bolsters Emyria’s capacity to accelerate the registration of our unique Ultra-Pure cannabinoid dose forms as well as drive further expansion and preclinical screening of our first-in-class, MDMA-inspired drug discovery program.”

“We look forward to providing further updates on these programs during 2023.”

Read the ASX release